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Background
Patients with R/M SCCHN have a poor prognosis, and
current therapies used after failure of first-line plati-
num-based chemotherapy provide transient, limited
benefit. SCCHN tumors are highly immunosuppressive
and evade immune detection by exploiting inhibitory
immune checkpoints such as the programmed cell death
ligand-1 (PD-L1)/programmed cell death-1 (PD-1) axis.
High mutational load and their relationship to human
papillomavirus (HPV) infection may make these tumors
amenable to immunotherapy. Durvalumab is a selective,
human IgG1 mAb that blocks binding of PD-L1: to PD-
1 (IC50 0.1 nM) and CD80 (IC50 0.04 nM). Tremelimu-
mab is a selective human IgG2 mAb inhibitor of
cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4).
The PD-1 and CTLA-4 pathways are non-redundant
and targeting both induces synergistic antitumor effects,
according to preclinical data, and was found to be active
and tolerable in a Phase Ib study in patients with
NSCLC (NCT02000947). Durvalumab monotherapy has
also shown preliminary antitumor activity in a Phase I/II
study in patients with solid tumors, including a SCCHN
cohort (NCT01693562). In a comprehensive clinical
development program of durvalumab in SCCHN, the
Phase III EAGLE study (NCT02369874) will investigate
the efficacy and safety of durvalumab as monotherapy
or in combination with tremelimumab versus SoC.
Methods
In this Phase III, open-label, multicenter, international
study, 720 patients with PD-L1+ and PD-L1– R/M
SCCHN will be randomized (1:1:1) to receive durvalu-
mab (10 mg/kg IV for up to 12 months); tremelimumab
(1 mg/kg IV) plus durvalumab (20 mg/kg IV for up to
12 months); or SoC (cetuximab, taxane, methotrexate,
or fluoropyrimidine) (Figure 1). Stratification factors
include PD-L1 status, HPV status and smoking history.
Eligible patients are immunotherapy naïve and have
progressed during or after treatment with a platinum-
containing regimen for R/M disease or progressed
within 6 months of multimodality therapy containing
platinum. Co-primary endpoints are progression-free
survival (PFS; RECIST v1.1), based on independent central
review and overall survival (OS). Secondary outcomes will
assess objective response rate, disease control rate, duration
of response, and proportion of patients alive and progres-
sion free at 6 and 12 months (using RECIST v1.1 and
immune-related RECIST criteria); safety (CTCAE v4.03)
and tolerability; and health-related quality of life. Explora-
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and potential biomarkers that may influence the progres-
sion of cancer and/or prospectively identify patients likely
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